Highlights VolitionRx Limited

Equities

VNRX

US9286611077

Real-time Estimate Cboe BZX Other stock markets 01:40:53 2024-04-30 pm EDT			5-day change	1st Jan Change
0.899 ^USD	+4.68%		+3.86%	+23.12%

Apr. 26	VolitionRx Limited Announces Board Changes	CI
Apr. 23	VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech	Apr. 23	CI
VolitionRx Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
VolitionRx Limited Agrees Supply Agreement with Fujifilm Vet Systems Co. Ltd	Mar. 20	CI
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
VolitionRx Limited and Veterinary Pathology Group joins forces to launch the Nu.Q(R) Vet Cancer Test to veterinary practices in the UK and Ireland	Nov. 06	CI
VolitionRx Limited Presents Breakthrough Liquid Biopsy Blood Test Method for Early-Stage Cancer	23-10-23	CI
VolitionRx Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
VolitionRx Seeks Acquisitions	23-05-31	CI
VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
VolitionRx Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
VolitionRx Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
VolitionRx Limited's Nu.Q(R) Vet Cancer Test Now Available for Pre-Order At the Point-Of-Care Through Heska Corporation	23-02-16	CI
VolitionRx to Seek Acquisitions	23-02-15	CI
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Volition Announces the Launch of the Nu.Q(R) Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories	22-11-03	CI
VolitionRx Limited Signs Global Supply Agreement for Nu.Q® Vet Cancer Test	22-10-20	CI
VolitionRx Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
Salarius Pharmaceuticals, VolitionRx Sign R&D Collaboration Deal	22-08-02	MT
Salarius Pharmaceuticals and VolitionRx Enters into Research and Development Collaboration Agreement	22-08-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights VolitionRx Limited

Equities

VNRX

US9286611077

Highlights

Filters